Cambridge Investment Research Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Cambridge Investment Research Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454K	Buy	1,704 +382	+29%	+$89.2K	﹤0.01%	3055
2026 Q1	$302K	Buy	1,322 +207	+19%	+$46.4K	﹤0.01%	3278
2025 Q4	$238K	Buy	1,115 +65	+6%	+$13.4K	﹤0.01%	3420
2025 Q3	$209K	Buy	+1,050	New	+$196K	﹤0.01%	3447
2025 Q1	–	Sell	-5,007	Closed	-$689K	–	3507
2024 Q4	$689K	Buy	+5,007	New	+$658K	﹤0.01%	2168

Other funds holding ASND

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Cambridge Investment Research Advisors's ASND Position: Q2 2026 in Review

Cambridge Investment Research Advisors increased its Ascendis Pharma A/S (ASND) stake by 29% in Q2 2026, buying an estimated $89.2K and bringing the position to 1,704 shares worth $454K. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Cambridge Investment Research Advisors first reported a position in ASND in Q4 2024 and has held it in 5 quarters since. The position peaked at $689K in Q4 2024. 313 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Cambridge Investment Research Advisors held 1,704 shares of Ascendis Pharma A/S worth $454K as of Q2 2026.
Cambridge Investment Research Advisors bought 382 Ascendis Pharma A/S shares in Q2 2026, an estimated $89.2K.
Ascendis Pharma A/S made up ﹤0.01% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #3055 holding.
Cambridge Investment Research Advisors first reported a position in Ascendis Pharma A/S in Q4 2024 and has held it in 5 quarters since.
Cambridge Investment Research Advisors's Ascendis Pharma A/S position peaked at $689K in Q4 2024.
313 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.